Stock Update (NASDAQ:OVAS): OvaScience Inc Welcomes John Howe, M.D., Former President and CEO of Project HOPE, to Board of Directors

OvaScience Inc (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced the appointment of John P. Howe, III, M.D., former President and Chief Executive Officer of Project HOPE, to the OvaScience Board of Directors.

“Dr. Howe’s many accomplishments, including overseeing Project HOPE through its expansion of international health education and humanitarian medical work over the past 14 years, have helped millions of people worldwide,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer and Co-Founder of OvaScience. “His commitment to serving the global unmet needs of patients is aligned with our mission to offer new fertility treatments to women who are in need of new options.”

Dr. Howe is a recognized expert in international medicine and is a humanitarian leader. From 2001 through 2015, he served as the President and Chief Executive Officer of Project HOPE, an international health education and humanitarian assistance foundation, which operates more than 70 programs in 45 countries on five continents. During Dr. Howe’s tenure, Project HOPE expanded its areas of distributing medicine, treating infectious diseases and non-communicable diseases, and promoting the health education and life improvement of women and children. Before Project HOPE, Dr. Howe held the Distinguished Chair in Health Policy at The University of Texas Health Science Center at San Antonio; he served as the Center’s chief executive from 1985 through 2000 and is currently the President Emeritus. He is a board member of BB&T Bank, the Chinese Center for Communicable Disease Control and Prevention, the John E. Fogarty International Center at the National Institutes of Health and the Texas Biomedical Research Institute, among others. Among Dr. Howe’s numerous honors and awards are the U.S. Army’s Commander’s Award for Public Service, the Surgeon General’s Exemplary Service Award and the Magnolia Award from the City of Shanghai, China. Dr. Howe is a published author of numerous articles, chapters and abstracts in medical journals, including the New England Journal of Medicine and the Annals of Internal Medicine, among others. Dr. Howe holds a Bachelor of Arts from Amherst College and an M.D. from Boston University School of Medicine.

“I believe OvaScience’s innovative approach to new treatments could make a major positive impact on how infertility challenges are addressed,” said Dr. Howe. “I look forward to joining the OvaScience team as the Company continues to grow internationally and its fertility treatments become more widely available to patients.” (Original Source)

Shares of OvaScience Inc closed yesterday at $36.19 . OVAS has a 1-year high of $55.69 and a 1-year low of $7.06. The stock’s 50-day moving average is $29.67 and its 200-day moving average is $37.49.

On the ratings front, OvaScience Inc has been the subject of a number of recent research reports. In a report issued on June 2, Wedbush analyst Zarak Khurshid reiterated a Buy rating on OVAS, with a price target of $52, which represents a potential upside of 43.7% from where the stock is currently trading. Separately, on May 18, Oppenheimer’s Rohit Vanjani reiterated a Buy rating on the stock and has a price target of $60.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Zarak Khurshid and Rohit Vanjani have a total average return of 5.6% and 38.1% respectively. Khurshid has a success rate of 65.9% and is ranked #1173 out of 3610 analysts, while Vanjani has a success rate of 79.5% and is ranked #21.

In total, 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $76.67 which is 111.9% above where the stock closed yesterday.

OvaScience Inc is a life science company engaged in discovery, development, and commercialization of new fertility treatments. Its patented technology is based on egg precursor cells found in the outer layer of a woman’s own ovaries.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts